An RNA-binding protein-related risk signature can predict the prognosis and tumor immunity of patients with testicular germ cell tumors

CONCLUSION: The established risk signature including four selected RBPs in TGCTs could predict the prognosis, tumor-related immunity and treatment benefits of patients with TGCTs. Utilization of this signature could help clinicians make personalized treatment decisions.PMID:35702133 | PMC:PMC9185064

Source: American Journal of Translational Research - June 15, 2022 Category: Research Authors: Yang Fu Shanshan Sun Jianbin Bi Chuize Kong Du Shi Source Type: research